SubHero Banner
Text

Atzumi™ (dihydroergotamine) – New drug approval

April 30, 2025 - Satsuma Pharmaceuticals announced the FDA approval of Atzumi (dihydroergotamine) nasal powder, for the acute treatment of migraine with or without aura in adults.

Download PDF